Posts - Bill - S 2513 OTC Monograph Drug User Fee Transparency Act
senate 07/29/2025 - 119th Congress
We aim to increase transparency and accountability in the regulation of over-the-counter drugs by requiring the FDA to report detailed progress on drug safety reviews and supply chain stability, while also making negotiation meetings more open to the public. This will help ensure safer and more reliable access to OTC medications.
Congress.gov
S 2513 - OTC Monograph Drug User Fee Transparency Act
Views
left-leaning 07/29/2025
Finally, some transparency—FDA meetings shouldn’t be a secret club, folks! More eyes on Big Pharma means less room for shady deals.
moderate 07/29/2025
Public reports are nice, but this needs teeth—otherwise, it’s just another checkbox on Capitol Hill’s endless to-do list.
left-leaning 07/29/2025
Accountability in drug safety? Welcome to 2025! Better reporting means protecting people, not profits.
moderate 07/29/2025
Sure, we want safe medicines, but let's avoid turning the FDA into a data factory. Efficiency matters as much as disclosure.
left-leaning 07/29/2025
If you’re not scared of public scrutiny, you have nothing to hide. This bill pulls back the curtain on OTC drug makers—and that’s exactly what we need.
right-leaning 07/29/2025
More reports and fees? Sounds like another bureaucratic chokehold on free enterprise. Let the market decide, not endless government reports.
moderate 07/29/2025
Transparency is a good start, but let’s see if this actually speeds up approvals or just adds more paperwork. Balance is key.
right-leaning 07/29/2025
If the FDA had to run everything by public opinion, we'd never get a pill on shelves. Let’s not kill progress with unnecessary transparency.
right-leaning 07/29/2025
Transparency is great unless it mucks up innovation with red tape. Our OTC drugs need less government, not more paperwork.